# A Clinical Study of Lutetium[177Lu] Oxodotreotide Injection in Patients With Advanced Neuroendocrine Neoplasms

Source: https://onco.cc/trials/nct06398444/  
OnCo record `nct06398444` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2/3 trial of Lutetium[177Lu] Oxodotreotide Injection in neuroendocrine tumours, run by Sinotau Pharmaceutical Group, now recruiting.

## Summary

A Clinical Study of Lutetium[177Lu] Oxodotreotide Injection in Patients With Advanced Neuroendocrine Neoplasms is a phase 2/3 interventional study registered as NCT06398444 by Sinotau Pharmaceutical Group, with 85 participants planned, started 2024-06-11 and due to reach its primary completion in 2027-06-01. Interventions recorded: Lutetium[177Lu] Oxodotreotide Injection.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06398444
- Phase: 2/3
- Setting: A Clinical Study to Evaluate the Safety and Efficacy of Lutetium[177Lu] Oxodotreotide Injection in Patients With Advanced Somatostatin Receptor Positive Neuroendocrine Neoplasms
- Sponsor: Sinotau Pharmaceutical Group
- Enrolled: 85

## Sources

- ClinicalTrials.gov NCT06398444: https://clinicaltrials.gov/study/NCT06398444

## Connected records

- cancers: [Neuroendocrine tumours](https://onco.cc/cancers/neuroendocrine/)
- companies: [Sinotau Pharmaceutical](https://onco.cc/companies/sinotau-pharmaceutical/)

---
JSON: https://onco.cc/api/v1/entities/nct06398444.json